PECA Labs

Executive Summary

PECA Labs is a Pittsburgh-based medical device company developing next-generation cardiovascular implants using a proprietary polymer platform. Their products, including vascular grafts and heart valves, feature radiopacity and controlled expandability, designed to improve longevity and performance in pediatric and adult patients. Founded in 2011, the company focuses on addressing unmet needs in congenital heart disease and vascular surgery. While still private and pre-revenue, PECA Labs' differentiated technology has potential to capture significant market share in the $5B+ cardiovascular implant market. The company's pipeline remains undisclosed, but its polymer platform could enable multiple product lines. Given the limited public data, PECA Labs represents an early-stage opportunity with technological promise but high execution risk.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for pediatric vascular graft40% success
• Q4 2026Series B funding round completion70% success
• Q2 2027First-in-human trial initiation for polymer heart valve50% success